As of 22 Nov 2026, Immunomatics has raised $100K across 1 verified round on record; latest: $100,000 strategic investment round, announced 7 Oct 2026.
Immunomatics, Inc. sells AI-based tools designed to enhance transplant donor-recipient risk assessment, primarily for healthcare providers in transplantation.
immunomatics.comHealthtechFounded 2024
3 sources · checked 2 times, last 45d ago
The release calls this a strategic investment, not a conventional priced round; no lead investor or valuation is stated.
Unlinked https://immunomatics.com/press/dr-keith-robison-invests-25000-in-immunomatics: Keith Robison's $25,000 of September 3, 2026 is its own investment, not part of Myosotis Investments' $100,000 of October 7
| Round | Amount | Announced | Lead | Buzz |
|---|---|---|---|---|
| Strategic investment [ REPORTED LATER ]: This round was announced before Fireround first saw it. It stays in the company's history, not in Latest, Trending, or alerts. | $100K | 2026-10-07 | not stated | No recent discussion |
3 sources · checked 2 times, last 45d ago [ VERIFIED · CORRECTED ] read against 1 of 3 sources
The release calls this a strategic investment, not a conventional priced round; no lead investor or valuation is stated. Unlinked https://immunomatics.com/press/dr-keith-robison-invests-25000-in-immunomatics: Keith Robison's $25,000 of September 3, 2026 is its own investment, not part of Myosotis Investments' $100,000 of October 7 | ||||
Also named as backers in company research: National Institutes of Health (NIH), NIH SBIR, Myosotis Investments B.V., Keith Robison, PhD, Georgia Nicholls